OncRef

Clinical Trial: NCT01881867

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Fred Hutchinson Cancer Center
Information Provided By:Fred Hutchinson Cancer Center
Last Update Posted:2019-07-09

Study Overview

Brief Summary

This randomized phase II trial studies how well glycosylated recombinant human interleukin-7 (CYT107) after vaccine therapy works in treating patients with castration-resistant prostate cancer that has spread to other areas of the body or has not responded to at least one type of treatment. Biological therapies, such as glycosylated recombinant human interleukin-7, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. It is not yet known whether glycosylated recombinant human interleukin-7 works better with or without vaccine therapy in treating prostate cancer.

Official Title

Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)

Conditions

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer

Intervention / Treatment

  • Biological: Glycosylated Recombinant Human Interleukin-7
  • Other: Laboratory Biomarker Analysis

Other Study ID Numbers

  • CITN12-03
  • NCI-2013-00998
  • CITN12-03
  • CITN12-03 IL7
  • CITN12-03
  • P30CA015704
  • P50CA097186
  • U01CA154967

Start Date (Actual)

2013-09-10

Primary Completion Date (Actual)

2017-05-15

Study Completion Date (Actual)

2018-01-02

Enrollment (Actual)

54

Study Type

Interventional

Phase

Phase 2